Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 5Phase 3 4Phase 1/2 2Phase 2/3 1

Status

Completed 4Active not recruiting 1

Sponsor Class

OTHER 7INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gynecologic 1Dermatologic 1

Conditions

Neoplasms 1522Carcinoma, Non-Small-Cell Lung 758Breast Neoplasms 572Neoplasm Metastasis 531Colorectal Neoplasms 448Melanoma 391Leukemia, Myeloid, Acute 372Multiple Myeloma 364Ovarian Neoplasms 354Recurrence 336Lymphoma 334Advanced Solid Tumors 325Lymphoma, Non-Hodgkin 315Prostatic Neoplasms 300Pancreatic Neoplasms 285Advanced Solid Tumor 240Stomach Neoplasms 233Carcinoma, Renal Cell 226Squamous Cell Carcinoma of Head and Neck 211Lung Neoplasms 210Solid Tumor 204Leukemia, Lymphocytic, Chronic, B-Cell 198Triple Negative Breast Neoplasms 185Solid Tumors 183Carcinoma, Hepatocellular 165Hematologic Neoplasms 155Head and Neck Neoplasms 153Lymphoma, Large B-Cell, Diffuse 148Lymphoma, Follicular 146Glioblastoma 145

Interventions

human papillomavirus vaccine, L1 type 16, 18 1halofantrine 1Papillomavirus Vaccines 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × Virus Diseases × Clear all
NCT05831111 2025-09-30

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

ModernaTX, Inc.

Phase 1 Active not recruiting
482 enrolled

Infections, Infectious Mononucleosis, Virus Diseases, Epstein-Barr Virus Infections

NCT04053283 2025-03-24

STAR

Akamis Bio

Phase 1 Completed
186 enrolled

Carcinoma, Neoplasm Metastasis, Virus Diseases

NCT03408587 2023-05-06

CLEVER

Viralytics

Phase 1 Completed
11 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Uveal Melanoma, Coxsackievirus Infections, Virus Diseases

NCT03852511 2022-06-24

FORTITUDE

Akamis Bio

Phase 1 Completed
28 enrolled

Carcinoma, Neoplasm Metastasis, Virus Diseases

NCT00541970 2018-08-17

Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs

GlaxoSmithKline

Phase 1 Completed
961 enrolled 43 charts
Gynecologic

Uterine Cervical Neoplasms, Virus Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡